[Use of no-protein blood extract for infertility and sterility (author's transl)]

In vitro studies into the effects of various concentrations of Solcoseryl (Solco, Basle, Switzerland) on selected asthenozoospermia patients have shown rise in motility in 26 per cent of the probands and decline in motility in 17 per cent. Spermatozoan motility was most strongly increased by a five per cent concentration of Solcoseryl.--Fifty-one patients, from whom different spermiographic findings had been earlier obtained, received ten injections of one ampoule of Solcoseryl daily, with weekend pauses inserted. Included were 46 oligozoospermia, 31 asthenozoospermia, and eight hypospermia. Spermiographic checks were undertaken on termination of therapy, and others followed two weeks, four weeks, three months, and six months after termination of therapy. They all gave improved findings, which were most unambiguous with regard to the number of spermia.--Findings were at least temporarily normal after treatment in 58 per cent of the patients with asthenozoospermia. The wives of eleven in 44 patients (25 per cent) with Solcoseryl treatment were pregnant after three months, as established in follow-up examinations. Artificial insemination was applied to 45 patients, among them 37 with maritogenic approach and eight cases with donogenic approach, using Solcoseryl. Eleven pregnancies were obtained from maritogenic insemination. Pregnancy was achieved in 38 per cent of the probands who received cryopreserved donor semen. These findings would not justify the claim of direct conception-producing action for Solcoseryl, in the context of insemination treatment.